



World Health Organization

Global Hepatitis Programme

Guideline development for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B

Management of conflicts of interest

Conflicts of interest were managed as follows:

1. All experts who participated in the process were required to complete the WHO Declaration of Interest (DOI) form before they commenced their work for WHO, and to promptly notify WHO if any change in the disclosed information occurred during the course of this work. The completed DOI forms were reviewed by the WHO Secretariat with a view to managing disclosed interests in the field of viral hepatitis.
2. At the meeting of the Guidelines Development Group in June 2014, a set of slides was projected to all meeting participants, which indicated each expert's disclosure of his/her declared interests. Hence, the GDG was aware of any existing interests among its members.
3. All declarations of interest were reviewed by the WHO Secretariat. It was decided that all experts could participate in the process but their interests should be disclosed in the guideline.
4. All relevant declared interests are summarized below.

Definition of potential financial conflict of interest

At the meeting of the Guidelines Development Group, the Secretariat of the WHO Global Hepatitis Programme considered predominant funding from a single company whose drug was being considered for use in the treatment of HBV (e.g. tenofovir by Gilead Sciences). The interest declared as stated by two Guidelines Development Group members (Tables 1 and 2), Lewis Robert and Anna Lok, posed a potential conflict of interest. However, in the case of Robert Lewis, the funding was for a community based screening project, and unrelated to treatment, and the amount received by Anna Lok from Gilead was less than US\$ 30 000 and equivalent to that from other companies. The Secretariat therefore concluded that these experts should not be excluded from actively taking part in formulating the recommendations during the meeting.

For the peer review group (Tables 3 and 4), the WHO secretariat was satisfied that there had been a transparent declaration of interests and no case necessitated exclusion from the review process.

Table 1. Members of the Guideline Development Group who declared no potential conflicts of interest

Last Name	First Name	Institution
Aghokeng	Avelin F	Virology Laboratory CREMER/IMPM/IRD (Cameroon)
Block	Joan	Hepatitis B Foundation (USA)
Khatib	Ahmed	Ministry of Health (Tanzania)
Khwairakpam	Giten	TREAT Asia/amFAR (Thailand)
Leung	Nancy	ASIAHEP Hong Kong Limited (Hong Kong)
Andrieux- Meyer	Isabelle	Médecins Sans Frontières (Switzerland)
Ocama	Ponsiano	Makerere College of Health Sciences (Uganda)
Qureshi	Huma	Pakistan Medical Research Council (Pakistan)
Strauss	Edna	School of Medicine, University of São Paulo (Brazil)
Sulaiman	Ali	University of Indonesia-Faculty of Medicine (Indonesia)

Table 2. Members of the Guideline Development Group who declared potential conflicts of interest

Last name	First Name	Institution	Nature of interest	Amount of income
Abraham	Priya	Christian Medical College & Hospital (India)	Drug resistance project funded by Indian Council of Medical Research	US\$ 53 944.782
Davalos Moscol	Milagros	Hospital Edgardo Rebagliati (Peru)	Consulting (Gilead, BMS, MSD, Bayer Schering, Pharma)	US\$ 8 000.00
			HCV research (Merck Sharp)	US\$ 3 000.00
El-Sayed	Manal Hamdy	Faculty of Medicine, Ain Shams University (Egypt)	Travel to conferences (MSD, Roche)	
Gore	Charles	World Hepatitis Alliance (UK)	WHA receives funding from 8 competing pharma companies involved in HCV drugs	
Han	Kwang Hyub	Yonsei University (South Korea)	Investigator of clinical trial of HBV antiviral (Gilead, Ildong Pharma); The Korean Association for the Study of the Liver (KASL) support travel	
Jia	Jidong	Beijing Friendship Hospital Capital Medical University (China)	Consulting (BMS, MSD, Novartis, Roche)	US\$ 1 000.00–2 000.00 once a year in the past 4 years
Lacombe	Karine	Hôpital Saint-Antoine, Sorbonne-Universités (France)	Advisory boards (Gilead, BMS)	US\$ 5 000.00
			Research grants (Gilead)	US\$ 15 000.00
Lesi	Olufunmilayo	University of Lagos and Lagos University Teaching Hospital (Nigeria)	Conference travel (Roche, Gilead), flight and hotel (one-time events)	
Lok	Anna	University of Michigan and American Association for the Study of Liver Diseases (USA)	Consultant, research grants (Gilead, GSK, Merck, Roche, BMS, Gilead)	US\$ 100 000.00
McMahon	Brian	Alaska Native Tribal Health Consortium (USA)	Consultation, funding to Liver Disease Program (payment sent to Alaska Native Tribal Health Consortium)	US\$ <5 000.00
Roberts	Lewis	Mayo Clinic (USA)	Consulting, research grants and speaking honorarium	US\$ 197 000.00 (161 494.80 from Gilead)
Thursz	Mark	Imperial College Faculty of Medicine (UK)	Consultancy on clinical trials in HBV infected patients (BMS)	€1500.00

			Honorarium for speaking at industry sponsored symposia (BMS)	€2 500.00
Yurdaydin	Cihan	University of Ankara Medical School (Turkey)	Advisory board member (Gilead, Merck, Janssen)	€4 000.00
			Speaker's bureau (Gilead, Roche, Merck)	€4500.00
			BMS (research unit)	€30 0000.00

Table 3. Members of the Peer Review Group who declared no potential conflicts of interest

Name	Institution
Serge Eholié	Unit of Infectious and Tropical Diseases, Treichville University Teaching Hospital, Abidjan (Côte d'Ivoire)
Samuel So	Asian Liver Center, Stanford University (USA)
Nikoloz Chkhartishvili	Infectious Diseases, AIDS and Clinical Immunology Research Center, (Georgia)
Mihai Voiculescu	Fundeni Clinical Institute (Romania)
Karen Kyuregyan	Chumakov Institute of Poliomyelitis and Viral Encephalitides (Russia)
Jude Byrne	International Network of People who Use Drugs (INPUD)
Gilles Wandeler	Department of Infectious Diseases, University Hospital Bern (Switzerland)
Adele Benzaken	Ministry of Health (Brazil)
Aaron Harris	Centers for Disease Control and Prevention (USA)
Geoff Beckett	Centers for Disease Control and Prevention (USA)
Shaffiq Essajee	Clinton Health Access Initiative (USA)
George Siberry	National Institutes of Health (USA)

Table 4. Members of the peer review group who declared potential conflicts of interest

Name	Institution	Nature of interest	Amount
Vincente Soriano	IdiPAZ-La Paz University Hospital & Autonomous University, Madrid (Spain)	Research support by Gilead and BMS on Drug resistance and safety profile for tenofovir and entecavir	Undisclosed
Seng Gee Lim	National University of Singapore (Singapore)	Research support for clinical trials on HBV, including provision of free PEG-interferon; by Merck, BMS, Novartis and Gilead Sciences	Provision of free PEG-interferon for 248 patients for 1 year US\$ 250 000; Provision of free drug supply of tenofovir for 132 patients for 2 years US\$ 350 000
Mark Sonderup	University of Cape Town and Groote Schuur Hospital (South Africa)	Travel support by Roche to attend liver meeting	US\$ 4 000.00
David Muljono	Eijkman Institute for Molecular Biology, (Indonesia)	Support for research reagents (for research unit given by Indonesian Ministry for Research and Technology); funding to research unit for operational cost of professorship by the Indonesian Academy of Sciences and the Royal Netherlands Academy of Arts and Sciences	US\$ 20 000.00 for research reagents, €12 000 for operational cost of professorship
Christian Trepo	INSERM - UCBL YON1 (France)	Consulting, research support, and travel by Flamel, Janssen, Roche, and BMS	Undisclosed